{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:41:57Z","timestamp":1785181317322,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clml.2023.06.005","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T16:07:05Z","timestamp":1687190825000},"page":"757-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET\/CT Imaging Following CAR-T Therapy"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9699-3080","authenticated-orcid":false,"given":"Forat","family":"Lutfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Goloubeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Kowatli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Gryaznov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0176-4857","authenticated-orcid":false,"given":"Dong W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-4272","authenticated-orcid":false,"given":"Rohan","family":"Dureja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie Y.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet H.","family":"Kocoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje","family":"Atanackovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-3562","authenticated-orcid":false,"given":"Aaron P.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wengen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.clml.2023.06.005_bib0001","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.06.005_bib0002","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2023.06.005_bib0003","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med [Internet]"},{"key":"10.1016\/j.clml.2023.06.005_bib0004","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI, et\u00a0al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet [Internet]. 2020;396(10254):839\u2013852. Available from https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673620313660. Access 18 July 2022","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"10.1016\/j.clml.2023.06.005_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2023.06.005_bib0006","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol [Internet]"},{"issue":"22","key":"10.1016\/j.clml.2023.06.005_bib0007","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv [Internet]"},{"issue":"9","key":"10.1016\/j.clml.2023.06.005_bib0008","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","article-title":"Day 30 SUVmax predicts progression in lymphoma patients achieving PR\/SD After CAR T-cell therapy","volume":"6","author":"Al Zaki","year":"2022","journal-title":"Blood Adv [Internet]"},{"issue":"27","key":"10.1016\/j.clml.2023.06.005_bib0009","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol [Internet]"},{"key":"10.1016\/j.clml.2023.06.005_bib0010","doi-asserted-by":"crossref","unstructured":"Inoue K, Goto R, Shimomura H, Fukuda H. FDG-PET\/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment. Springerplus [Internet]. 2013;2(1):113. Available from https:\/\/pubmed.ncbi.nlm.nih.gov\/23543853. Access 18 July 2022","DOI":"10.1186\/2193-1801-2-113"},{"key":"10.1016\/j.clml.2023.06.005_bib0011","unstructured":"Delbeke D, Coleman RE, Guiberteau MJ, et\u00a0al. Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0. J Nucl Med [Internet]. 2006;47(5). 885 LP \u2013895Available from http:\/\/jnm.snmjournals.org\/content\/47\/5\/885.abstract. Access 18 July 2022"},{"issue":"2","key":"10.1016\/j.clml.2023.06.005_bib0012","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00259-013-2579-4","article-title":"Quantitative assessment of global lung inflammation following radiation therapy using FDG PET\/CT: a pilot study","volume":"41","author":"Abdulla","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging [Internet]"},{"key":"10.1016\/j.clml.2023.06.005_bib0013","unstructured":"Seraj SM, Zadeh MZ, Werner TJ, et\u00a0al. Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease. Am J Nucl Med Mol Imaging [Internet]. 2019;9(5):248\u2013254. Available from https:\/\/pubmed.ncbi.nlm.nih.gov\/31772823. Access 18 July 2022"},{"key":"10.1016\/j.clml.2023.06.005_bib0014","doi-asserted-by":"crossref","unstructured":"Jacobson CA, Hunter B, Armand P, et\u00a0al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood [Internet]. 2018;132:92. Available from https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497119361415. Access 18 July 2022","DOI":"10.1182\/blood-2018-99-117199"},{"issue":"1","key":"10.1016\/j.clml.2023.06.005_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40164-021-00248-9","article-title":"Elevated LDH greater than 400 U\/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort","volume":"10","author":"Rabinovich","year":"2021","journal-title":"Exp Hematol Oncol [Internet]"},{"issue":"14","key":"10.1016\/j.clml.2023.06.005_bib0016","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv [Internet]"},{"issue":"8","key":"10.1016\/j.clml.2023.06.005_bib0017","first-page":"E209","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol [Internet]"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:23Z","timestamp":1761871403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2152265023001878"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.06.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET\/CT Imaging Following CAR-T Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}